高缺血风险患者药物洗脱支架植入12个月后:氯吡格雷单药对比延长双联抗血小板治疗
A-CLOSE研究为韩国开放标签非劣效随机试验,纳入3203例药物洗脱支架植入12个月后具有高临床或病变风险特征的患者,1:1随机接受氯吡格雷单药或延长DAPT(氯吡格雷+阿司匹林)。24个月净不良临床事件(全因死亡、心梗、支架血栓、卒中或BARC 2/3/5型出血复合终点)单药组5.0% vs DAPT组5.1%(风险差-0.1个百分点,90%CI -1.3至1.2,非劣效P=0.001)。关键次要缺血终点单药组3.7% vs 1.6%(HR 2.33,95%CI 1.47-3.69,P<0.001),BARC 2/3/5型出血单药组1.8% vs 4.1%(HR 0.43,95%CI 0.27-0.67,P<0.001)。
要点
- 高缺血风险患者DES植入12个月后,氯吡格雷单药24个月净不良临床事件不劣于延长DAPT(5.0% vs 5.1%,风险差-0.1个百分点,90%CI -1.3至1.2,非劣效P=0.001)。
- 氯吡格雷单药组关键次要缺血终点(全因死亡、心梗、支架血栓或卒中)显著高于延长DAPT组(3.7% vs 1.6%,HR 2.33,95%CI 1.47-3.69,P<0.001)。
- 氯吡格雷单药组BARC 2/3/5型出血显著低于延长DAPT组(1.8% vs 4.1%,HR 0.43,95%CI 0.27-0.67,P<0.001)。
- 两组严重不良事件发生率相似。
- 该研究为开放标签设计,非劣效界值为2.3个百分点,主要终点为24个月净不良临床事件。
适用人群与场景
- 韩国纳入的具有高临床或病变风险特征、药物洗脱支架植入已满12个月的患者。
- 排除人群原文未提及。
诊断标准与关键阈值
- 非劣效界值为2.3个百分点,主要终点为24个月净不良临床事件(全因死亡、心肌梗死、支架血栓、卒中或BARC 2/3/5型出血的复合终点)。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 开放标签非劣效随机试验,韩国单国多中心(中心数原文未提及),共3203例随机:氯吡格雷单药组1601例,延长DAPT组1602例。
- 主要终点24个月净不良临床事件:单药组80例(5.0%)vs DAPT组81例(5.1%),风险差-0.1个百分点(90%CI -1.3至1.2),非劣效P=0.001。
- 关键次要缺血终点(全因死亡、心梗、支架血栓或卒中):单药组60例(3.7%)vs DAPT组26例(1.6%),HR 2.33(95%CI 1.47-3.69),P<0.001。
- 关键次要出血终点(BARC 2/3/5型):单药组28例(1.8%)vs DAPT组65例(4.1%),HR 0.43(95%CI 0.27-0.67),P<0.001。
- 严重不良事件发生率两组相似。
证据类型、等级与局限
- 证据类型:开放标签、非劣效随机对照试验(RCT)。
- 局限:开放标签设计;单国研究(韩国);非劣效界值2.3个百分点;关键次要缺血终点显示单药组事件增加,需权衡缺血与出血风险。
对床旁实践的改变
- 对于DES植入12个月后高缺血风险患者,氯吡格雷单药可作为延长DAPT的替代选择以减少出血,但需注意缺血事件(包括支架血栓、心梗、卒中、死亡)增加的风险。
- 不适用于原文未提及的人群;临床决策需个体化权衡缺血与出血风险。
指南或共识出处
- A-CLOSE试验(ClinicalTrials.gov NCT03947229),发表于N Engl J Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of clopidogrel monotherapy as compared with extended dual antiplatelet therapy (DAPT) with clopidogrel and aspirin beyond 12 months after implantation of a drug-eluting stent remains uncertain in patients at high risk for recurrent ischemic events.
METHODS: In this open-label noninferiority trial conducted in South Korea, we enrolled patients with high-risk clinical or lesion characteristics in whom a drug-eluting stent had been implanted 12 months earlier and randomly assigned them, in a 1:1 ratio, to receive clopidogrel monotherapy or extended DAPT (clopidogrel plus aspirin). The primary end point was net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding at 24 months (noninferiority margin, 2.3 percentage points). Key secondary ischemic and bleeding end points were tested in a prespecified hierarchical order.
RESULTS: Of the 3203 patients who underwent randomization, 1601 were assigned to receive clopidogrel monotherapy and 1602 to receive extended DAPT. Over the course of 24 months, a primary end-point event occurred in 80 patients (5.0%) in the monotherapy group and in 81 (5.1%) in the DAPT group (risk difference, -0.1 percentage points; 90% confidence interval [CI], -1.3 to 1.2; P = 0.001 for noninferiority). Death from any cause, myocardial infarction, stent thrombosis, or stroke (the key secondary ischemic end point) occurred in 60 patients (3.7%) in the monotherapy group and in 26 (1.6%) in the DAPT group (hazard ratio, 2.33; 95% CI, 1.47 to 3.69; P<0.001). BARC type 2, 3, or 5 bleeding (the key secondary bleeding end point) occurred in 28 patients (1.8%) in the monotherapy group and in 65 (4.1%) in the DAPT group (hazard ratio, 0.43; 95% CI, 0.27 to 0.67; P<0.001). The incidence of serious adverse events was similar in the two groups.
CONCLUSIONS: Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months. (Funded by Chong Kun Dang and Samjin; A-CLOSE ClinicalTrials.gov number, NCT03947229.).
参考来源
- Lee SJ, Lee YJ, Lee K, et al. Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients. N Engl J Med. 2026. PMID: 42670964. doi:10.1056/NEJMoa2608533
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。